In the last trading session, 27.45 million Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) shares changed hands as the company’s beta touched 0.53. With the company’s per share price at $1.43 changed hands at $0.11 or 8.33% during last session, the market valuation stood at $3.07M. CYCC’s last price was a discount, traded about -607.69% off its 52-week high of $10.12. The share price had its 52-week low at $0.75, which suggests the last value was 47.55% up since then. When we look at Cyclacel Pharmaceuticals Inc’s average trading volume, we note the 10-day average is 1.83 million shares, with the 3-month average coming to 327.64K.
Analysts gave the Cyclacel Pharmaceuticals Inc (CYCC) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended CYCC as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Cyclacel Pharmaceuticals Inc’s EPS for the current quarter is expected to be -0.55.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) trade information
Instantly CYCC was in green as seen at the end of in last trading. With action 75.81%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -46.44%, with the 5-day performance at 75.81% in the green. However, in the 30-day time frame, Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) is 44.44% up. Looking at the short shares, we see there were 47934.0 shares sold at short interest cover period of 1.51 days.
Cyclacel Pharmaceuticals Inc (CYCC) estimates and forecasts
Data shows that the Cyclacel Pharmaceuticals Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -20.11% over the past 6 months, a 91.44% in annual growth rate that is considerably higher than the industry average of 17.20%. Year-over-year growth is forecast to reach -90.50% down from the last financial year.
The company’s revenue for the corresponding quarters a year ago was 16k and 31k respectively.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 32.13%. The 2024 estimates are for Cyclacel Pharmaceuticals Inc earnings to increase by 88.30%.
CYCC Dividends
Cyclacel Pharmaceuticals Inc is expected to release its next quarterly earnings report in November.
Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 4.82% of Cyclacel Pharmaceuticals Inc shares while 18.03% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 18.94%.
